The global HPV testing and PAP test market size reached USD 4.4 Billion in 2024. Looking forward, the research expects the market to reach USD 7.0 Billion by 2033, exhibiting a growth rate (CAGR) of 4.96% during 2025-2033.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
Human papillomavirus (HPV) is a sexually transmitted infection (STI) that causes cancer of the cervix, oropharynx, penis, and vulva. It can be detected with the support of various tests and procedures, such as HPV and Papanicolaou (PAP) test. These assessments comprise microscopic observation of specimens and cervical, head and neck cancer screening. Amongst these, HPV tests are deployed for assessing the presence of human papillomavirus that precede the development of genital warts, whereas PAP tests are used for determining changes in the cell and the presence of abnormal cells in cervices.
HPV Testing and PAP Test Market Trends:
The increasing prevalence of cervical cancer, especially amongst the adult demographics. due to presence of papillomavirus is facilitating the need for novel, technologically advanced, and cost-effective HPV and PAP screening, which is one of the major factors primarily driving the market growth. In line with this, the introduction of machine-assisted, plasma- and cell-free deoxyribonucleic acid (DNA) screenings to detect and monitor the treatment response of HPV-infected cancers at the early phase is acting as another growth-inducing factor.This is further supported by the continuous clinical trials, developments, and product launches by key players, such as the easy-to-use home HPV screening test, on account of the sudden outbreak of coronavirus disease (COVID-19) pandemic, is providing them with a competitive edge in the market. Other factors, such as the rapid expansion in the healthcare sector and the numerous favorable initiatives undertaken by the government bodies and the non-governmental organizations (NGOs) for sensitizing people regarding the causes of cervical cancer and the benefits of having HPV and PAP tests are creating a positive outlook for the market.
Key Market Segmentation:
The research provides an analysis of the key trends in each sub-segment of the global HPV testing and PAP test market report, along with forecasts at the global, regional and country level from 2025-2033. Our report has categorized the market based on test type, product, application and end user.Breakup by Test Type:
- HPV Test
- Pap Test
- Co-testin.
Breakup by Product:
- Instruments
- Consumables
- Service.
Breakup by Application:
- Cervical Cancer Screening
- Vaginal Cancer Screenin.
Breakup by End User:
- Hospitals and Clinics
- Laboratories
- Diagnostic Centers
- Other.
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Afric.
Competitive Landscape:
The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Arbor Vita Corporation, AstraZeneca plc, Becton Dickinson and Company, Biocon Limited, bioMérieux SA, Danaher Corporation, F. Hoffmann-La Roche AG, Hologic Inc., NURX Inc. (Thirty Madison Inc.), Qiagen N.V., Quest Diagnostics Incorporated, Seegene Inc. and Thermo Fisher Scientific Inc.Key Questions Answered in This Report
- How big is the global HPV testing and PAP test market?
- What is the expected growth rate of the global HPV testing and PAP test market during 2025-2033?
- What are the key factors driving the global HPV testing and PAP test market?
- What has been the impact of COVID-19 on the global HPV testing and PAP test market?
- What is the breakup of the global HPV testing and PAP test market based on the test type?
- What is the breakup of the global HPV testing and PAP test market based on the product?
- What is the breakup of the global HPV testing and PAP test market based on the application?
- What is the breakup of the global HPV testing and PAP test market based on the end user?
- What are the key regions in the global HPV testing and PAP test market?
- Who are the key players/companies in the global HPV testing and PAP test market?
Table of Contents
1 Preface3 Executive Summary12 Value Chain Analysis14 Price Analysis
2 Scope and Methodology
4 Introduction
5 Global HPV Testing and PAP Test Market
6 Market Breakup by Test Type
7 Market Breakup by Product
8 Market Breakup by Application
9 Market Breakup by End User
10 Market Breakup by Region
11 SWOT Analysis
13 Porters Five Forces Analysis
15 Competitive Landscape
List of Figures
List of Tables
Companies Mentioned
- Abbott Laboratories
- Arbor Vita Corporation
- AstraZeneca plc
- Becton Dickinson and Company
- Biocon Limited
- bioMérieux SA
- Danaher Corporation
- F. Hoffmann-La Roche AG
- Hologic Inc.
- NURX Inc. (Thirty Madison Inc.)
- Qiagen N.V.
- Quest Diagnostics Incorporated
- Seegene Inc.
- Thermo Fisher Scientific Inc
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 149 |
Published | June 2025 |
Forecast Period | 2024 - 2033 |
Estimated Market Value ( USD | $ 4.4 Billion |
Forecasted Market Value ( USD | $ 7 Billion |
Compound Annual Growth Rate | 5.3% |
Regions Covered | Global |
No. of Companies Mentioned | 14 |